AAPL350.78-2.00 (-0.57%) ▼|ABBV293.17-1.39 (-0.47%) ▼|ABT105.84-1.61 (-1.50%) ▼|ACN241.03-6.67 (-2.69%) ▼|ADBE237.25-8.75 (-3.56%) ▼|AMAT344.15-6.11 (-1.74%) ▼|AMD489.82-14.47 (-2.87%) ▼|AMGN459.74-2.58 (-0.56%) ▼|AMT189.23-1.51 (-0.79%) ▼|AMZN256.70-1.05 (-0.41%) ▼|AVGO338.53+5.13 (+1.54%) ▲|AXP315.62-3.43 (-1.08%) ▼|BA164.60-0.62 (-0.38%) ▼|BAC49.24-0.84 (-1.68%) ▼|BKNG154.89-2.64 (-1.68%) ▼|BLK1,185.20-12.77 (-1.07%) ▼|BMY60.92-2.01 (-3.19%) ▼|BNY149.90-1.79 (-1.18%) ▼|BRK-B591.48-1.38 (-0.23%) ▼|C119.40-1.92 (-1.58%) ▼|CAT566.19-4.30 (-0.75%) ▼|CL100.35-0.64 (-0.63%) ▼|CMCSA25.59-0.02 (-0.06%) ▼|COF187.81-5.41 (-2.80%) ▼|COP141.20+0.68 (+0.48%) ▲|COST1,114.66+0.92 (+0.08%) ▲|CRM197.02-17.81 (-8.29%) ▼|CSCO94.94+0.42 (+0.44%) ▲|CVS86.54-2.05 (-2.31%) ▼|CVX216.46-0.68 (-0.31%) ▼|DE650.88-3.11 (-0.48%) ▼|DHR227.20-2.71 (-1.18%) ▼|DIS118.68-0.02 (-0.02%) ▼|DUK130.54-0.05 (-0.04%) ▼|EMR160.23-0.42 (-0.26%) ▼|FDX321.08-6.57 (-2.01%) ▼|GD357.52-2.18 (-0.60%) ▼|GE325.54+0.36 (+0.11%) ▲|GEV768.58+5.01 (+0.66%) ▲|GILD171.02+3.44 (+2.05%) ▲|GM84.24+0.63 (+0.75%) ▲|GOOG279.14-2.12 (-0.75%) ▼|GOOGL281.98-1.74 (-0.61%) ▼|GS877.40-14.14 (-1.59%) ▼|HD339.93-7.58 (-2.18%) ▼|HON221.82+3.87 (+1.78%) ▲|IBM233.41-9.10 (-3.75%) ▼|INTC54.04-1.40 (-2.53%) ▼|INTU327.00-18.56 (-5.37%) ▼|ISRG432.60-5.15 (-1.18%) ▼|JNJ279.69-2.86 (-1.01%) ▼|JPM330.55-7.67 (-2.27%) ▼|KO99.24-0.25 (-0.25%) ▼|LIN522.47-0.99 (-0.19%) ▼|LLY1,415.99-15.68 (-1.10%) ▼|LMT590.15+4.94 (+0.84%) ▲|LOW223.15-1.79 (-0.79%) ▼|LRCX208.72-2.11 (-1.00%) ▼|MA649.67-12.04 (-1.82%) ▼|MCD277.11+2.44 (+0.89%) ▲|MDLZ67.49-0.06 (-0.08%) ▼|MDT103.14+0.26 (+0.25%) ▲|META622.83-3.58 (-0.57%) ▼|MMM181.87+0.19 (+0.10%) ▲|MO78.16-0.75 (-0.94%) ▼|MRK144.11-0.36 (-0.25%) ▼|MS183.37-2.21 (-1.19%) ▼|MSFT503.42-14.58 (-2.81%) ▼|MU701.73-17.30 (-2.41%) ▼|NEE85.07-0.27 (-0.32%) ▼|NFLX59.68-1.07 (-1.76%) ▼|NKE37.32-0.95 (-2.47%) ▼|NOW93.10-6.27 (-6.31%) ▼|NVDA153.92-2.22 (-1.42%) ▼|ORCL114.48-4.61 (-3.87%) ▼|PEP143.64-2.79 (-1.91%) ▼|PFE28.51-0.36 (-1.23%) ▼|PG172.95-0.08 (-0.04%) ▼|PLTR156.81-3.58 (-2.23%) ▼|PM196.99+0.95 (+0.48%) ▲|QCOM167.13-1.39 (-0.82%) ▼|RTX197.32+2.43 (+1.25%) ▲|SBUX108.31-0.41 (-0.38%) ▼|SCHW91.20-1.75 (-1.88%) ▼|SO93.97-0.68 (-0.71%) ▼|SPG232.09-0.69 (-0.30%) ▼|T22.54+0.18 (+0.78%) ▲|TMO690.62-0.71 (-0.10%) ▼|TMUS170.21+0.20 (+0.12%) ▲|TSLA380.51+0.77 (+0.20%) ▲|TXN294.97+0.76 (+0.26%) ▲|UBER69.29-0.70 (-1.00%) ▼|UNH396.23-15.79 (-3.83%) ▼|UNP299.89-3.82 (-1.26%) ▼|UPS110.96-0.86 (-0.77%) ▼|USB59.45-0.98 (-1.62%) ▼|V419.49-6.97 (-1.63%) ▼|VZ46.33-0.01 (-0.02%) ▼|WFC82.89-1.95 (-2.30%) ▼|WMT127.83-0.58 (-0.45%) ▼|XOM167.44+0.57 (+0.34%) ▲|AAPL350.78-2.00 (-0.57%) ▼|ABBV293.17-1.39 (-0.47%) ▼|ABT105.84-1.61 (-1.50%) ▼|ACN241.03-6.67 (-2.69%) ▼|ADBE237.25-8.75 (-3.56%) ▼|AMAT344.15-6.11 (-1.74%) ▼|AMD489.82-14.47 (-2.87%) ▼|AMGN459.74-2.58 (-0.56%) ▼|AMT189.23-1.51 (-0.79%) ▼|AMZN256.70-1.05 (-0.41%) ▼|AVGO338.53+5.13 (+1.54%) ▲|AXP315.62-3.43 (-1.08%) ▼|BA164.60-0.62 (-0.38%) ▼|BAC49.24-0.84 (-1.68%) ▼|BKNG154.89-2.64 (-1.68%) ▼|BLK1,185.20-12.77 (-1.07%) ▼|BMY60.92-2.01 (-3.19%) ▼|BNY149.90-1.79 (-1.18%) ▼|BRK-B591.48-1.38 (-0.23%) ▼|C119.40-1.92 (-1.58%) ▼|CAT566.19-4.30 (-0.75%) ▼|CL100.35-0.64 (-0.63%) ▼|CMCSA25.59-0.02 (-0.06%) ▼|COF187.81-5.41 (-2.80%) ▼|COP141.20+0.68 (+0.48%) ▲|COST1,114.66+0.92 (+0.08%) ▲|CRM197.02-17.81 (-8.29%) ▼|CSCO94.94+0.42 (+0.44%) ▲|CVS86.54-2.05 (-2.31%) ▼|CVX216.46-0.68 (-0.31%) ▼|DE650.88-3.11 (-0.48%) ▼|DHR227.20-2.71 (-1.18%) ▼|DIS118.68-0.02 (-0.02%) ▼|DUK130.54-0.05 (-0.04%) ▼|EMR160.23-0.42 (-0.26%) ▼|FDX321.08-6.57 (-2.01%) ▼|GD357.52-2.18 (-0.60%) ▼|GE325.54+0.36 (+0.11%) ▲|GEV768.58+5.01 (+0.66%) ▲|GILD171.02+3.44 (+2.05%) ▲|GM84.24+0.63 (+0.75%) ▲|GOOG279.14-2.12 (-0.75%) ▼|GOOGL281.98-1.74 (-0.61%) ▼|GS877.40-14.14 (-1.59%) ▼|HD339.93-7.58 (-2.18%) ▼|HON221.82+3.87 (+1.78%) ▲|IBM233.41-9.10 (-3.75%) ▼|INTC54.04-1.40 (-2.53%) ▼|INTU327.00-18.56 (-5.37%) ▼|ISRG432.60-5.15 (-1.18%) ▼|JNJ279.69-2.86 (-1.01%) ▼|JPM330.55-7.67 (-2.27%) ▼|KO99.24-0.25 (-0.25%) ▼|LIN522.47-0.99 (-0.19%) ▼|LLY1,415.99-15.68 (-1.10%) ▼|LMT590.15+4.94 (+0.84%) ▲|LOW223.15-1.79 (-0.79%) ▼|LRCX208.72-2.11 (-1.00%) ▼|MA649.67-12.04 (-1.82%) ▼|MCD277.11+2.44 (+0.89%) ▲|MDLZ67.49-0.06 (-0.08%) ▼|MDT103.14+0.26 (+0.25%) ▲|META622.83-3.58 (-0.57%) ▼|MMM181.87+0.19 (+0.10%) ▲|MO78.16-0.75 (-0.94%) ▼|MRK144.11-0.36 (-0.25%) ▼|MS183.37-2.21 (-1.19%) ▼|MSFT503.42-14.58 (-2.81%) ▼|MU701.73-17.30 (-2.41%) ▼|NEE85.07-0.27 (-0.32%) ▼|NFLX59.68-1.07 (-1.76%) ▼|NKE37.32-0.95 (-2.47%) ▼|NOW93.10-6.27 (-6.31%) ▼|NVDA153.92-2.22 (-1.42%) ▼|ORCL114.48-4.61 (-3.87%) ▼|PEP143.64-2.79 (-1.91%) ▼|PFE28.51-0.36 (-1.23%) ▼|PG172.95-0.08 (-0.04%) ▼|PLTR156.81-3.58 (-2.23%) ▼|PM196.99+0.95 (+0.48%) ▲|QCOM167.13-1.39 (-0.82%) ▼|RTX197.32+2.43 (+1.25%) ▲|SBUX108.31-0.41 (-0.38%) ▼|SCHW91.20-1.75 (-1.88%) ▼|SO93.97-0.68 (-0.71%) ▼|SPG232.09-0.69 (-0.30%) ▼|T22.54+0.18 (+0.78%) ▲|TMO690.62-0.71 (-0.10%) ▼|TMUS170.21+0.20 (+0.12%) ▲|TSLA380.51+0.77 (+0.20%) ▲|TXN294.97+0.76 (+0.26%) ▲|UBER69.29-0.70 (-1.00%) ▼|UNH396.23-15.79 (-3.83%) ▼|UNP299.89-3.82 (-1.26%) ▼|UPS110.96-0.86 (-0.77%) ▼|USB59.45-0.98 (-1.62%) ▼|V419.49-6.97 (-1.63%) ▼|VZ46.33-0.01 (-0.02%) ▼|WFC82.89-1.95 (-2.30%) ▼|WMT127.83-0.58 (-0.45%) ▼|XOM167.44+0.57 (+0.34%) ▲|
13.9 C
New York
Tuesday, November 17, 2026

Energy

University of Phoenix leaders present on artificial intelligence, academic policy, leadership development and workplace innovation at PACRAO 2026

Conference participation included presentations on emerging higher education topics and professional development initiativesPHOENIX, Nov. 17, 2026 /PRNewswire/ -- University of Phoenix leaders presented on artificial intelligence, academic policy management,...

My Green Condo Inc. Opens Patented Blockchain Accounting Framework (U.S. Patent No. 12,443,952) to SaaS Providers for M&A and Strategic Licensing

Building on its 2026 blockchain and tokenization roadmap, MGCOne invites legacy property management software...

Atain Appoints Jitendra Sindhwani (Jimpy) as Chief Executive Officer

WASHINGTON and GURGAON, India, Nov. 18, 2026 /PRNewswire/ -- Atain, an enterprise orchestration partner...

Summary in Progress: Anticipate Insights and Updates Soon

Palmetto Publishing, the author, presents a transformative journey of self-discovery and creativity, promising insights...

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of...

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of...

The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England...

PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P<0.0001...

The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England...

PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P<0.0001...

Borr Drilling Limited – Prospector 5 Rig Incident

HAMILTON, Bermuda, October 25, 2026 /PRNewswire/ -- Borr Drilling Limited (NYSE and OSE: BORR) ("Borr Drilling") confirms that an incident occurred at approximately 20:37 local...

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor,...

New data on Lilly’s investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G12C-mutant...

2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC

SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development,...

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

SHAOXING, China, Oct. 25, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma")  will publish the phase...

Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026

BEIJING, Oct. 24, 2026 /PRNewswire/ -- Likang Life Sciences ("Likang"), a biotechnology company advancing AI-enabled personalized cancer immunotherapies, sponsored and exhibited at the Abu Dhabi...

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than TripledLate-Breaking Phase 3 DeLLphi-305 Results Presented in...

Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026

BEIJING, Oct. 24, 2026 /PRNewswire/ -- Likang Life Sciences ("Likang"), a biotechnology company advancing AI-enabled personalized cancer immunotherapies, sponsored and exhibited at the Abu Dhabi...

Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026

BEIJING, Oct. 24, 2026 /PRNewswire/ -- Likang Life Sciences ("Likang"), a biotechnology company advancing AI-enabled personalized cancer immunotherapies, sponsored and exhibited at the Abu Dhabi...

Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026

GUANGZHOU, China, Oct. 24, 2026 /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars, today announced the presentation...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.